2026-525939-17-00Not yet recruitingPhase 1
An open-label, DDI study to investigate the effects of duvakitug on the PK of selected cytochrome P450 substrates
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Sept 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 3 Jul 2026
- Start date
- 13 Oct 2026
- Lead sponsor
- Sanofi-Aventis Recherche & Developpement
- Diseases
- Ulcerative colitis
- EU CT number
- 2026-525939-17-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 50
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Research Organisation GmbH Coordinator of this site? Confirm its status | Berlin | Germany | Not yet recruiting |
| Kommunale Traegergesellschaft Cottbus mbH Coordinator of this site? Confirm its status | Cottbus | Germany | Not yet recruiting |
| LMU Klinikum Muenchen AöR Coordinator of this site? Confirm its status | Munich | Germany | Not yet recruiting |
| Universitaetsklinikum Ulm AoR Coordinator of this site? Confirm its status | Ulm | Germany | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.